Public Company

Capricor Therapeutics


Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways.


Founded 2005
Type Public
Location San Diego, California, USA


CAPR $4.49 2.05% $0.09

Latest News

Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Mar 15, 2023 GlobeNewswire Inc. -Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); Plan to Report on Interim Analysis in...
Capricor Therapeutics Receives Clinical Research Forum’s 2023 Top Ten Clinical Research Achievement Award Mar 02, 2023 GlobeNewswire Inc. -HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement- -HOPE-2 Trial Recognized as an Outstanding Accomplishment in Research Advancement-
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan Feb 16, 2023 GlobeNewswire Inc. -Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise-
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program Jan 19, 2023 GlobeNewswire Inc. -Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy-
Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform Jan 12, 2023 GlobeNewswire Inc. -StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins-